[Anti-inflammatory role of cholinergic and serotonergic systems in shock].
Development of anaphylactic shock initiated with the horse serum (anaphylactic index = 4.0 +/- 0.0 arbitrary units) leads to acute decrease in spleen concentration of serotonin (in shock--0.443 +/- 0.005; basal level--1.532 +/- 0.004 ng per mg of protein). Unlike of anaphylaxis, development of endotoxic shock in rats, caused by introduction of a sublethal dose (20 mg/kg) of lipopolysaccharide, results in acute increase in serotonin concentration (at a shock--56.588 +/- 0.006, basal level--5.465 +/- 0.005 ng per mg of protein) and marked tachycardia (+76 +/- 8, intact rats--+2 +/- 1 beats per min). Administration of atropine with galantamine leads to the most essential decrease of anaphylactic reaction (1.5 +/- 0.3 arbitrary units). Administration of choline alfoscerate (-16 +/- 3 beats per min) or galantamine (+9 +/- 2 beats per min) significantly reduces tachycardia. Data show, that inhibition of the central cholinergic mechanisms leads to increase and their excitation--to decrease in activity of the spleen serotonergic system. So, spleen concentration of serotonin is connected with a target of shock defeat (lungs or heart).
Nezhinskaia
G I
GI
Vladykin
A L
AL
Sapronov
N S
NS
D000707:Anaphylaxis / Q000276:immunology / Q000378:metabolism* / Q000517:prevention & control; D000818:Animals; D002800:Cholinesterase Inhibitors / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D004195:Disease Models, Animal; D004347:Drug Interactions; D006168:Guinea Pigs; D008297:Male; D018721:Muscarinic Agonists / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D018727:Muscarinic Antagonists / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D018722:Nicotinic Agonists / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D051381:Rats; D017208:Rats, Wistar; D011950:Receptors, Cholinergic / Q000378:metabolism*; D011985:Receptors, Serotonin / Q000378:metabolism*; D012701:Serotonin / Q000378:metabolism; D012772:Shock, Septic / Q000276:immunology / Q000378:metabolism* / Q000517:prevention & control; D013154:Spleen / Q000187:drug effects / Q000276:immunology / Q000378:metabolism*
D002800:Cholinesterase Inhibitors; D018721:Muscarinic Agonists; D018727:Muscarinic Antagonists; D018722:Nicotinic Agonists; D011950:Receptors, Cholinergic; D011985:Receptors, Serotonin; D012701:Serotonin